Ceftaroline: Potential role and implications in an era of escalating antimicrobial resistance

American Journal of Health-System Pharmacy

Volumn 68, Issue 6, 2011, Pages 489-

  Chahine, Elias B ^a  

^a PALM BEACH ATLANTIC UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM; AZTREONAM; BETA LACTAMASE AMPC; CEFTAROLINE; EXTENDED SPECTRUM BETA LACTAMASE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; CHLAMYDOPHILA PNEUMONIAE; COST EFFECTIVENESS ANALYSIS; EDITORIAL; HAEMOPHILUS INFLUENZAE; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIAE; PRESCRIPTION; PRIORITY JOURNAL; SKIN INFECTION;

EID: 79955999383     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100424     Document Type: Editorial

References (9)

1. Howden BP, Davies JK, Johnson PD et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010; 23:99-139.
2. Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med. 2010; 16:217-25.
3. Lim L, Sutton E, Brown J. Ceftaroline: a new broad-spectrum cephalosporin. Am J Health-Syst Pharm. 2011; 68:491-8.
4. Corey GR, Wilcox MH, Talbot GH et al. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010; 65(suppl 4):iv41-51.
5. Wilcox MH, Corey GR, Talbot GH et al. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010; 65(suppl 4):iv53-65.
6. File TM Jr, Low DE, Eckburg PB et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis. 2010; 51:1395-405.
7. Vidaillac C, Leonard SN, Sader HS et al. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009; 53:2360-6.
8. Forest Laboratories. Our product pipeline: solid, and set for further growth. www.frx.com/research/pipeline.aspx (accessed 2011 Jan 1).
9. Mushtaq S, Warner M, Ge Y et al. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother. 2007; 60:300-11. (Pubitemid 47243878)